TITLE

Portraits in Proteomics

AUTHOR(S)
Janssen, Deborah
PUB. DATE
April 2004
SOURCE
Bio-IT World;Apr2004, Vol. 3 Issue 4, p50
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Presents information on identifying protein biomarkers to help detect and diagnose cancer in the U.S. Efforts of biotechnology companies to search for proteins that may serve as biomarkers for early detection of cancer; Conduction of complementary protein-specific antigen tests among cancer patients; Assertion of the National Cancer Institute (NCI) - Food and Drug Administration Clinical Proteomics Program on the use of mass spectrometry; Collaboration of the National Institute of Standards and Technology with the NCI to validate early detection cancer biomarkers. INSETS: Nuclear Weapons;Peak Performance;Resources to Enhance Biomarker Discovery.
ACCESSION #
14173958

 

Related Articles

  • A Perspective on Challenges and Issues in Biomarker Development and Drug and Biomarker Codevelopment. Taube, Sheila E.; Clark, Gary M.; Dancey, Janet E.; McShane, Lisa M.; Sigman, Caroline C.; Gutman, Steven I. // JNCI: Journal of the National Cancer Institute;11/4/2009, Vol. 101 Issue 21, p1453 

    A workshop sponsored by the National Cancer Institute and the US Food and Drug Administration addressed past lessons learned and ongoing challenges faced in biomarker development and drug and biomarker codevelopment. Participants agreed that critical decision points in the product life cycle...

  • Burzynski RIDES AGAIN FDA AGREES TO LET PATIENTS GET CONTROVERSIAL DRUG.  // Investigate;Apr/May2014, Vol. 10 Issue 143, p22 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) to let cancer patients get the controversial drug of Dr. Stanislaw Burzynski, who claims that he can treat difficult brain tumours with a new class of drugs he has invented. According to the U.S. National Cancer...

  • Meaningful progress in therapy options. Polansky, Maura; Ross, Alicia C. // JAAPA: Journal of the American Academy of Physician Assistants (;Apr2009, Vol. 22 Issue 4, p51 

    The article focuses on the report released by the National Cancer Institute (NCI) which shows progress in colorectal cancer, which is the second common cancer in the U.S. NCI has estimated 148,810 cases of colorectal cancer in 2008 with the approval of new drugs from the U.S. Food and Drug...

  • Biomarkers Key to Better Drugs. Frank, Richard // Drug Discovery & Development;May2006, Vol. 9 Issue 5, p72 

    The article reports on the recognition of the U.S. Food and Drug Administration on the critical need for accelerated development of biomarkers and their use in tandem with advanced therapeutics to improve diagnosis and treatment. The collaborative agreement, the Oncology Biomarker Qualification...

  • 'Master protocol' aims to revamp cancer trials. Ledford, Heidi // Nature;6/13/2013, Vol. 498 Issue 7453, p146 

    The article focuses on renewed efforts put in by the Washington D.C.-based Friends of Cancer Research group to treat lung cancer. Lung cancer in late stage trials has been shown curable in 2 out of 20 patients with the help of biomarkers. This group, which as support of the U.S. National Cancer...

  • I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy. Barker, A. D.; Sigman, C. C.; Kelloff, G. J.; Hylton, N. M.; Berry, D. A.; Esserman, L. J. // Clinical Pharmacology & Therapeutics;Jul2009, Vol. 86 Issue 1, p97 

    I-SPY 2 (investigation of serial studies to predict your therapeutic response with imaging and molecular analysis 2) is a process targeting the rapid, focused clinical development of paired oncologic therapies and biomarkers. The framework is an adaptive phase II clinical trial design in the...

  • FDA clears biomarker test for ovarian cancer.  // Biomedical Market Newsletter;9/12/2011, Vol. 21, p152 

    The article reports on the approval of a biomarker test for ovarian cancer by the Food and Drug Administration (FDA) which is showing greatest specificity in estimating ovarian cancer risk of in women with a pelvic mass in the U.S.

  • New biomarker method could increase cancer diagnostic tests. FORD, OMAR // Medical Device Daily;7/1/2009, Vol. 13 Issue 125, p1 

    The article discusses the results of the Clinical Proteomic Technology Assessment for Cancer study, which indicated the possible use of biomarkers for the development of cancer detection methods. Sponsored by the U.S. National Cancer Institute, the study highlighted the potential of a new method...

  • NCI awards Labcyte $196K for cancer biomarker program.  // Medical Device Daily;11/9/2011, Vol. 15 Issue 215, p10 

    The article reports on the 196,000-U.S.-dollar grant received by Labcyte from the National Cancer Institute (NCI) for the company's cancer biomarker validation program with the Canary Center of Stanford University in Palo Alto, California. The program aims to develop an advanced system that...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics